QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-upgrades-madrigal-pharmaceuticals-to-overweight

Cantor Fitzgerald analyst Prakhar Agrawal upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Neutral to Overweight.

 citizens-maintains-market-outperform-on-madrigal-pharmaceuticals-raises-price-target-to-527

Citizens analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and raises the ...

 madrigal-pharmaceuticals-q3-eps-508-misses-216-estimate-sales-287268m-beat-245386m-estimate

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(5.08) per share which missed the analyst consensus estima...

 b-of-a-securities-upgrades-madrigal-pharmaceuticals-to-neutral-raises-price-target-to-445

B of A Securities analyst Alexandria Hammond upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Underperform to Neutral an...

 madrigal-pharmaceuticals-announces-multiple-mash-and-rezdiffra-data-presentations-at-the-aaslds-the-liver-meeting-nov-711-2025

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis ...

 piper-sandler-maintains-overweight-on-madrigal-pharmaceuticals-raises-price-target-to-540

Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and raises the price...

 truist-securities-initiates-coverage-on-madrigal-pharmaceuticals-with-buy-rating-announces-price-target-of-580

Truist Securities analyst Srikripa Devarakonda initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy ratin...

 oppenheimer-maintains-outperform-on-madrigal-pharmaceuticals-raises-price-target-to-590

Oppenheimer analyst Jay Olson maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and raises the price target...

 6-stocks-goldman-sachs-says-are-poised-for-potential-acquisition-in-next-12-months--including-a-huge-200-winner

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

 a-glimpse-into-the-expert-outlook-on-madrigal-pharmaceuticals-through-7-analysts

In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and...

 b-riley-securities-maintains-buy-on-madrigal-pharmaceuticals-raises-price-target-to-560

B. Riley Securities analyst Mayank Mamtani maintains Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Buy and raises the price...

 canaccord-genuity-maintains-buy-on-madrigal-pharmaceuticals-raises-price-target-to-526

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price targe...

 hc-wainwright--co-assumes-madrigal-pharmaceuticals-at-buy-announces-price-target-of-500

HC Wainwright & Co. analyst Andrew S. Fein assumes Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announce...

 gyre-therapeutics-gains-attention-as-under-the-radar-liver-fibrosis-drug-maker

HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fib...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION